Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor

Molecular Pharmacology

Volumn 53, Issue 1, 1998, Pages 166-175

  Holst, Birgitte ^a   Zoffmann, Sannah ^a   Elling, Christian E ^a   Hjorth, Siv A ^a   Schwartz, Thue W ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; ALANINE; ASPARTIC ACID; CAM 4092; ELEDOISIN; HISTIDINE; LANEPITANT; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ A; NOLPITANTIUM; PHOSPHATIDYLINOSITOL; SERINE; SUBSTANCE P; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING SITE; LIGAND BINDING; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOSPECIFICITY;

EID: 0031914895     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.1.166     Document Type: Article

References (47)

1. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12:1693-1703.
2. Berridge MJ, Dawson MC, Downes CP, Heslop JP, and Irvin RF (1983) Changes in the level of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J 212:473-482.
3. 1 receptor antagonists. Bioorg Med Chem 2:357-370.
4. Clackson T and Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science (Washington DC) 267:383-386.
5. Elling CE, Nielsen SM, and Schwartz TW (1995) Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor. Nature (Lond) 374:74-77.
6. Elling CE and Schwartz TW (1996) Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. EMBO J 15:6213-6219.
7. 2) receptor antagonist. Regul Pept 46:31-36.
8. Emonds-Alt X, Doutremepuich J-D, Heaulme M, Hneliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux J-P, Proietto V, Broeck DV, Soubrié P, Fur GL, and Breliére J-C (1993b) In vitro and vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 antagonist. Eur J Pharmacol 250:403-413.
9. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Washington DC) 274:768-770.
10. Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, and Strader CD (1993) Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP96345. Nature (Lond) 362:350-353.
11. Fong TM, Huang RC, and Stader CD (1992) Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. J Biol Chem 267:25664-25667.
12. Fong TM, Yu H, Cascieri MA, Underwood D, Swain CJ, and Strader CD (1994a) The role of histidine 265 in antagonist binding to the neurokinin-1 receptor. J Biol Chem 269:2728-2732.
13. Fong TM, Yu H, Cascieri MA, Underwood D, Swain CJ, and Strader CD (1994b) Interaction of glutamine 165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists. J Biol Chem 269:14957-14961.
14. Fujii T, Morimoto M, Maeda Y, Yamaoka M, Hagiwara D, Miyake H, Ikari N, and Matsuo M (1992) Pharmacological profile of a high affinity dipeptide NK-1-receptor antagonist, FK888. Br J Pharmacol 107:785-789.
15. Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel J-F, Blanchard J-C, and Landuron PM (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 88:10208-10212.
16. Gether U, Johansen TE, and Schwartz TW (1993a) Chimeric NK1 (substance P) NK3 (neurokinin B) receptors. J Biol Chem 268:7893-7898.
17. Gether U, Johansen TE, Snider RM, Lowe JA III, Nakanishi S, and Schwartz TW (1993b) Different binding epitopes on the NK1 receptor for substance P and a non-peptide antagonist. Nature 362:345-348.
18. Gether U, Emonds-Alt X, Breliére J-C, Fujii T, Hagiwara D, Pradier L, Garret C, Johansen TE, and Schwartz TW (1994a) Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor. Mol Pharmacol 45:500-508.
19. Gether U, Nilsson L, Lowe JA III, and Schwartz TW (1994b) Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345. J Biol Chem 269:23959-23964.
20. Gitter BD, Bruns RF, Howbert JJ, Waters DC, Threlkeld PG, Cox LM, Nixon JA, Lobb KL, Mason NR, Stengel PW, Cockerham SL, Silbaugh SA, Gehlert DR, Schober DA, Iyengar S, Calligaro DO, Regoli D, and Hipskind PA (1995) Pharmacological characterization of LY303870: a novel potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J Pharmacol Exp Ther 275:1-8.
21. Horton RM, Hunt HD, Ho SN, Pullen JK, and Pease LR (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
22. Huang RC, Vicario PP, Strader CD, and Fong TM (1995) Identification of residues involved in ligand binding to the neurokinin-2 receptor. Biochemistry 34:10048-10055.
23. Huang RC, Yu H, Strader CD, and Fong TM (1994) Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry 33:3007-3013.
24. Johansen TE, Schøller MS, Tolstoy S, and Schwartz TW (1990) Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors. FEBS Lett 267:289-294.
25. Kage R, Leeman SE, Krause JE, Costello CE, and Boyd ND (1996) Identification of Methionine as the site of covalent attachment of a p-benzoyl-phenylalanine-containing analogue of substance P on the substance P (NK-1) receptor. J Biol Chem 271:25797-25800.
26. Kenakin TP (1995) Agonist-receptor efficacy. I: Mechanism of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192.
27. Kenakin TP (1996) Receptor conformational induction versus selection: all part of the same energy landscape. Trends Pharmacol Sci 17:190-191.
28. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
29. Lefkowitz RJ, Cotecchia S, Samama PS, and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
30. Li Y, Marnerakis M, Stimson ER, and Maggio JE (1995) Mapping peptide-binding domains of the substance P (NK-1) receptor from P338D1 cells with photolabile agonists. J Biol Chem 270:1213-1220.
31. 3H)-cis-3(2-Methoxybenzyl)amino-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand. J Med Chem 36:3197-3201.
32. Rosenkilde MM, Cahir M, Gether U, Hjorth SA, and Schwartz TW (1994) Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J Biol Chem 269:28160-28164.
33. Schertler GFX, Villa C, and Henderson R (1993) Projection structure of rhodopsin. Nature (Lond) 362:770-772.
34. Schilling W, Bittiger H, Brugger F, Criscione L, Hauser K, Ofner S, Olpe HR, Vassout A, and Veenstra S (1993) Perspectives in Medicinal Chemistry (Testa B, ed) pp 207-220, Verlag Helvetica Chim Acta, Basel, Switzerland.
35. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotech 5:434-444.
36. Schwartz TW, Gether U, Schambye HT, and Hjorth SA (1995) Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharmaceut Design 1:325-342.
37. Schwartz TW and Rosenkilde MM (1996) Is there a 'lock' for all 'keys' in 7TM receptors? Trends Pharmacol Sci 17:213-216.
38. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, and Bourne HR (1996) Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature (Lond) 383:347-350.
39. 1) receptor. Science (Washington DC) 251:435-439.
40. Stappert J, Wirsching J, and Kemler R (1992) PCR method for introducing mutations into cloned DNA by joining an internal primer to a tagged flanking primer. Nucl Acids Res 20:624-625.
41. Strader CD, Fong TM, Tota MR, and Underwood D (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132.
42. Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, Patchett AA, and Dixon RAF (1991) Allele-specific activation of genetically engineered receptors. J Biol Chem 266:5-8.
43. Strange PG (1996) The energetics of ligand binding at catecholamine receptors. Trends Pharmacol Sci 17:238-244
44. Strosberg AD (1993) Structure, function and regulation of adrenergic receptors. Protein Sci 2:1198-1209.
45. Tabert M and Peyronel J-F (1994) Synthesis of RPR100893, prototype of a new series of potent and selective nonpeptide NK1 antagonists: the triarylperhydroisoindolols. Bioorg Med Chem Lett 4:673-676.
46. Wieland K, Zuurmond HM, Krasel C, IJzerman AP, and Lohse MJ (1996) Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta2-adrenergic receptor. Proc Natl Acad Sci USA 93:9276-9281.
47. Zoffman S, Gether U, and Schwartz TW (1993) Conserved His VI-17 of the NK-1 receptor is involved in binding of non-peptide antagonists but not substance P. FEBS Lett 336:506-510.